Promotional content developed and funded by Novartis Pharmaceuticals UK Ltd
for UK healthcare professionals only

Prescribing information Adverse event reporting information 

INGRAIN-MF
Incorporating genetics, risk and associated burden into MF management

MODULE 4: Optimising management of myelofibrosis and evaluating the use of JAK inhibitors

Introduction

Over the last 15 years, the treatment landscape for myelofibrosis (MF) has changed with the introduction of JAK inhibitors, which can be used to treat MF-related splenomegaly or constitutional symptoms.1-3 However, JAK inhibitors and other medicinal therapies are largely palliative in nature, with allogeneic stem cell transplantation representing the only hope of cure for patients with MF.4

Ruxolitinib is indicated for the treatment of disease‑related splenomegaly or symptoms in adult patients with primary MF (also known as chronic idiopathic MF), post polycythaemia vera MF or post essential thrombocythaemia MF.1

In this module, you will learn about:

  • different treatment options for patients with MF
  • the efficacy and tolerability profiles of JAK inhibitors in controlling MF‑related splenomegaly and symptoms
  • the practicalities and considerations for the use of ruxolitinib

Multiple-choice questions (MCQs) to test your current knowledge

These MCQs will help you assess your current knowledge of this topic before you begin to work through the module. Your answers will be marked but will not count towards your final score. You will be asked the same MCQs at the end of the module. You will be able to download a learning certificate for your records upon completion.

JAK: Janus kinase

Continue to section 1: Treatment landscape in myelofibrosis 
Homepage

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard.
Adverse events should also be reported to Novartis online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report or alternatively email medinfo.uk@novartis.com or call 01276 698370

References
  1. Ruxolitinib Summary of Product Characteristics. Available at: medicines.org.uk
  2. Pardanani A, Harrison C et al. Safety and efficacy of fedratinib in patients with primary or secondary myelofibrosis: a randomized clinical trial. JAMA Oncol 2015;1:643-651
  3. Venugopal S, Mascarenhas J. Novel therapeutics in myeloproliferative neoplasms. J Hematol Oncol 2020;13:162
  4. Vannucchi A M, Barbui T et al. Philadelphia chromosome-negative chronic myeloproliferative neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2015;26 Suppl 5:v85-99